Inventor

SCHEINBERG DAVID A

US37 patents

⚠️ This page may combine multiple inventors who share the name “SCHEINBERG DAVID A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

SCHEINBERG DAVID A

SCHEINBERG DAVID A

T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2

Immunogenic WT-1 peptides and methods of use thereof

WT1 HLA class II-binding peptides and compositions and methods comprising same

Single wall nanotube constructs and uses therefor

Single wall nanotube constructs and uses thereof

Targeted self-assembly of functionalized carbon nanotubes on tumors

Alpha emitting constructs and uses thereof

Single wall nanotube constructs and uses thereof

Targeted self-assembly of functionalized carbon nanotubes on tumors

One-step labeling of antibodies to high specific activity with actinium-225

Alpha-emitting constructs and uses thereof

Single wall nanotube constructs and uses thereof

Compositions and methods for treating cancer and other diseases

MEMORIAL SLOAN KETTERING CANCER CENTER

WT1 HLA class II-binding peptides and compositions and methods comprising same

Compositions and methods for adoptive cell therapy for cancer

T cell receptor-like antibodies specific for a PRAME peptide

Immunogenic WT-1 peptides and methods of use thereof

Immunogenic WT-1 peptides and methods of use thereof

Compositions and methods for adoptive cell therapy for cancer

Inflammasome-targeted RNA interference approach to treating kidney injury and disease

Immunogenic WT-1 peptides and methods of use thereof

T cell receptor-like antibodies specific for Foxp3-derived peptides

Monoclonal antigen-binding proteins to intracellular oncogene products

Method and composition for targeted delivery of therapeutic agents

Compositions and methods for adoptive cell therapy

Compositions and methods for treating cancer and other diseases

SLOAN KETTERING INST CANCER

Increasing antibody affinity by altering glycosylation of immunoglobulin variable region

Therapeutic use of hypervariable region of monoclonal antibody M195 and constructs thereof

Synthetic HLA binding WT-1 peptide analogues and uses thereof

Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof

WT1 HLA class II—binding peptides and compositions and methods comprising same

Oncogene fusion protein peptide vaccines

Prostate specific antigens and uses thereof

Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen

Method of inhibitor design and identification using a 3-D structure of human peptide deformylase

PROTEIN DESIGN LABS INC

Antibodies with increased binding affinity

Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region